2017 Clinical Trials Conditions DEA 
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD. Clinical Trials and Human Subject Protections. DEA and the Controlled Substances Act.
Cannabis Law Report
JULY 9, 2021
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
MARCH 4, 2020
Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
Cannabis Law Report
MARCH 21, 2019
Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. If you reside in any of the following 15 states, there are laws stating certain conditions must be met in order to legally obtain CBD.
Canna Law Blog
MARCH 4, 2020
Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). The post The Ketamine Clinic Craze: Legalities and Possibilities appeared first on Harris Bricken.
Cannabis Law Report
JANUARY 11, 2019
Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. IMAJ, FEBRUARY 2017.
Expert insights. Personalized for you.
52 
Let's personalize your content